A Study of Neoadjuvant TCHpy（Pyrotinib ，Trastuzumab，Carboplatin and Paclitaxel）for ER+/HER2+ Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Neoadjuvant
Interventions: DRUG: pyrotinib,Trastuzumab，carboplatin，Albumin paclitaxel
Sponsor: Wuhan Union Hospital, China